Latest Breaking News On - Stephen barker - Page 6 : comparemela.com

Japan-listed stock of Shin Nippon (SNBL), which acquired the drug through its purchase of Satsuma Pharmaceuticals in April last year, was down 12.2% at 1,721 yen ($11.64) at Thursday's close. SNBL said the complete response letter from the Food and Drug Administration (FDA) did not indicate any concerns related to the data nor was there any request for additional information.

United statesRyoichi nagataKhushi mandowaraPuyaan singhEli lillyKrishna chandra eluriStephen barkerDrug administrationJapan based shin nippon biomedical laboratorieShin nipponSatsuma pharmaceuticalsChief executive officerFood and drug administrationSatsuma pharmaceuticalsStephen barker